Smart insulin pump could ease diabetes in cystic fibrosis patients
NCT ID NCT05562492
First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This study tests whether a hybrid closed-loop system (CamAPS FX) can improve blood sugar control in people aged 16 and older with cystic fibrosis-related diabetes. The system combines an insulin pump, continuous glucose monitor, and smartphone app to automatically adjust insulin. Over 26 weeks, researchers will compare this approach to standard insulin therapy with glucose monitoring in 128 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS-RELATED DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
All Wales Adult CF Centre
Cardiff, United Kingdom
-
Belfast City Hospital
Belfast, United Kingdom
-
Glenfield Hospital
Leicester, United Kingdom
-
Kings College Hospital
London, United Kingdom
-
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, United Kingdom
-
Royal Brompton Hospital
London, United Kingdom
-
Royal Papworth Hospital
Cambridge, United Kingdom
-
Royal Stoke University Hospital
Stoke-on-Trent, United Kingdom
-
Southampton General Hospital
Southampton, United Kingdom
-
St Bartholomew's Hospital
London, United Kingdom
-
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom
-
Wythenshawe Hospital, Manchester University NHS Foundation Trust
Manchester, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CamAPS FX hybrid closed-loop system (insulin pump, continuous glucose monitor, and smartphone app)
What this could lead to
If successful, this could offer a more automated and effective way to manage blood sugar in cystic fibrosis-related diabetes, potentially reducing complications and improving quality of life.
What could go wrong
This is a relatively small, early-stage trial (128 participants) and the technology may not work for everyone. There are risks of device malfunction or hypoglycemia, and the system requires 24/7 wear and training.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.